Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Autori principali: Antonio Lacquaniti (Autore), Patrizio Pasqualetti (Autore), Teresa Casuscelli di Tocco (Autore), Susanna Campo (Autore), Stefania Rovito (Autore), Maurizio Bucca (Autore), Antonino Ragusa (Autore), Paolo Monardo (Autore)
• Natura: Libro
• Pubblicazione: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...